Prevention and control of viral hepatitis in the Russian Federation in the Russian Federation: Lessons learnt and the way forward
October 25-26, 2018 - Moscow, Russia
Meeting objectives:
-
Review the epidemiological situation on viral hepatitis and burden of disease in the Russian Federation;
-
Provide an overview of surveillance systems for viral hepatitis and infectious diseases;
-
Discuss achievements and challenges in the prevention of viral hepatitis, the possible implementation of new prevention strategies in Russia;
-
Give an overview of the current approaches to chronic viral hepatitis treatment;
-
Discuss the current issues of organization of medical care and access to treatment for patients with viral hepatitis;
-
Discuss the development and implementation of a national plan of action to control viral hepatitis in Russia;
-
Evaluate what is still needed to achieve the viral hepatitis elimination goals defined by WHO Global Strategy and WHO’s Regional office for Europe
-
Discuss the successes, issues and barriers to overcome, and the way forward.
Thursday, October 25th
OPENING AND OBJECTIVES
Chairs: Pierre Van Damme (VHPB, Belgium) and Vladimir Chulanov (Russia)
09:00-09:20
-
Welcome and opening
-
Introduction of the participants
-
Introduction of the VHPB
-
Objectives of the meeting:
-
Review of the meeting programme
Welcome by:
-
The Russian Federation Ministry of Health representative
-
Rospotrebnarzor representative
-
Rector/Vice-rector of Sechenov University
-
The WHO Representative in the Russian Federation
-
VHPB Executive Secretary
SESSION 1: THE HEALTH CARE SYSTEM IN THE RUSSIAN FEDERATION
Chairs: Daniel Lavanchy (VHPB, Switzerland) and Igor Nikitin (Russia)
Elena Malinnikova, Chief Specialist on infectious diseases of MoH, Moscow;
Vladimir Gorodin, Chief Specialist on Infectious Diseases in the Southern Federal district, Krasnodar.
Natalia Kostenko, Department of Science, Innovative Development and Management of Medical and Biological Health Risks, Ministry of Health, Moscow.
10:05 - 10:20 Challenges and prospects of the organization and financing of medical care.
Vitaly Omelyanovskiy, Center for Healthcare Quality Assessment and Control of the Russian Federation MoH, Moscow.
10:20 - 10:30 Questions and discussion
SESSION 2: SURVEILLANCE AND EPIDEMIOLOGY OF VIRAL HEPATITIS IN RUSSIA
Chairs: Helène Norder (VHPB, Sweden) and Elena Malinnikova (Russia)
Vladimir Chulanov, Central Research Institute of Epidemiology, Moscow.
Mikhail Mikhailov, Russian Medical Academy of Continuous Professional Education, Moscow.
Elena Esaulenko, Pasteur Institute of Epidemiology and Microbiology, Saint Petersburg.
Olga Isayeva, I.I. Mechnikov Institute of vaccines and sera, Moscow.
Nikolay Pimenov, Central Research Institute of Epidemiology, Moscow.
State-of-art lecture
Antons Mozalevskis, WHO Regional Office for Europe, Copenhagen, Denmark.
12:50 - 13:00 Questions and discussion
SESSION 3: EPIDEMIOLOGY AND DISEASE BURDEN OF VIRAL HEPATITIS IN THE REGIONS OF THE RUSSIAN FEDERATION
Chairs: Paolo Bonanni (VHPB, Italy) and Olga Znoyko (Russia)
Olga Sagalova, Chief specialist on infectious diseases of the Chelyabinsk Region MoH, Chelyabinsk.
Viktoria Bakhtina, Specialized clinical infectious diseases hospital of Krasnodar Region MoH, Krasnodar.
Anna Simakova, The Far Eastern State Medical University, Vladivostok.
Snezhana Sleptsova, M.K.Amosov North-Eastern Federal University, Yakutsk.
Marina Ivanova, AIDS and Infectious Diseases Center of the Kabardino-Balkaria Republic MoH, Nalchik.
Alexey Krapivkin, Chukotka District Hospital, Anadyr.
State-of-art lecture
John Ward, Centers for Disease Control and Prevention, Atlanta, USA.
15:20 - 15:30 Questions and discussion
SESSION 4: PREVENTION OF VIRAL HEPATITIS. VIRAL HEPATITIS IN RISK GROUPS.
17:40 - 17:50 Questions and discussion
SESSION 5: THE ROLE OF CIVIL SOCIETY IN THE RESPONS TO VIRAL REPATITIS IN RUSSIA
18:20 - 18:30 Questions and discussion
Friday, October 26th
SESSION 6: WHO GLOBAL HEALTH SECTOR STRATEGY AND EUROPEAN PLAN OF ACTION ON VIRAL HEPATITIS. TREATMENT OF VIRAL HEPATITIS.
Chairs: David Goldberg (VHPB, Scotland) and Olga Sagalova (Russia)
09:45 - 10:00 The system of drug supply of patients with viral hepatitis in the Russian Federation: how to make treatment more accessible?
Elena Maksimkina, Department of drug supply and regulation of medical products handling, Ministry of Health, Moscow.
State-of-art lecture
10:35 - 10:45 Questions and discussion
SESSION 7: NATIONAL ACTION PLAN ON ELIMINATION OF VIRAL HEPATITIS AS A PUBLIC HEALTH THREAT IN THE RUSSIAN FEDERATION BY 2030: STRATEGIC DIRECTIONS, PRIORITIES AND TARGETS
Chairs: Liudmila Mosina (VHPB, WHO-Euro) and Dzhamal Abdurakhamnov (Russia)
11:00 - 12:15 Discussion in groups: What needs to be done to achieve the targets for eliminating viral hepatitis in Russia by 2030?
-
Group 1 - Epidemiological surveillance, screening, monitoring and analysis of the effectiveness of prevention and treatment programs, informing the public
-
Group 2 - Prevention of viral hepatitis: improvement of vaccine prevention programs, prevention in high-risk groups, prevention in health care settings
-
Group 3 - Treatment of viral hepatitis: recommendations based on epidemiology and disease burden data, increasing access to treatment, coverage of the most affected groups
-
Group 4 - Funding of screening, prevention and treatment programs: mechanisms for ensuring sustainable financing, dialogue between the state and pharmaceutical companies, prospects for reducing prices for medicines, financing of treatment in outpatient settings
-
Group 5 - Innovations in health care: research priorities, mechanisms to promote scientific development, accelerate the introduction of promising developments in the practice
12:15 - 12:45 Presentation of the results of the discussion in groups
SESSION 8: PANEL DISCUSSION: " INCREASING THE ACCESS TO TREATMENT OF CHRONIC VIRAL HEPATITIS IN THE RUSSIAN FEDERATION: THE ROLE OF THE STATE, BUSINESS AND THE PROFESSIONAL COMMUNITY "
12:45 - 13:45 Panel members: Moderator Mojca Maticic (VHPB, Slovenia)
-
Antons Mozalevskis, WHO Regional Office for Europe;
-
Elena Maksimkina, Department of drug supply and regulation of medical products handling, Ministry of Health;
-
Igor Nikitin, Therapeutic and rehabilitation center of the Russian Federation MoH; Pirogov Russian National Research Medical University;
-
Inna Zheleznyakova, Center for Healthcare Quality Assessment and Control of the Russian Federation MoH;
-
Elena Malinnikova, Chief Specialist on infectious diseases of the Russian Federation MoH;
-
Vladimir Chulanov, Central Research Institute of Epidemiology;
-
Mikhail Samsonov, Pharmaceutical company “R-Pharm”;
-
Sergey Golovin, The International Treatment Preparedness Coalition: Eastern Europe and Central Asia
SESSION 9: CONCLUSIONS OF THE MEETING
Chairs: Pierre Van Damme (VHPB, Belgium) and Vladimir Chulanov (Russia)